137 related articles for article (PubMed ID: 8005584)
1. Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines.
Runnebaum IB; Tong XW; Moebus V; Heilmann V; Kieback DG; Kreienberg R
Hum Genet; 1994 Jun; 93(6):620-4. PubMed ID: 8005584
[TBL] [Abstract][Full Text] [Related]
2. Exon 5 of the p53 gene is a target for deletions in ovarian cancer.
Angelopoulou K; Levesque MA; Katsaros D; Shipman R; Diamandis EP
Clin Chem; 1998 Jan; 44(1):72-7. PubMed ID: 9550561
[TBL] [Abstract][Full Text] [Related]
3. Multiplex PCR (MPCR) Screening Can Detect Small Intragenic p53 Deletion and Insertion Mutations.
Runnebaum IB; Wang-Gohrke S
Methods Mol Med; 2001; 39():329-35. PubMed ID: 21340788
[TBL] [Abstract][Full Text] [Related]
4. Identification of deletions and insertions in the p53 gene using multiplex PCR and high-resolution fragment analysis: application to breast and ovarian tumors.
Angelopoulou K; Diamandis EP
J Clin Lab Anal; 1998; 12(4):250-6. PubMed ID: 9671178
[TBL] [Abstract][Full Text] [Related]
5. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
[TBL] [Abstract][Full Text] [Related]
6. Poor correlation with loss of heterozygosity on chromosome 17p and p53 mutations in ovarian cancers.
Sakamoto T; Nomura N; Mori H; Wake N
Gynecol Oncol; 1996 Nov; 63(2):173-9. PubMed ID: 8910623
[TBL] [Abstract][Full Text] [Related]
7. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines.
Yaginuma Y; Westphal H
Cancer Res; 1992 Aug; 52(15):4196-9. PubMed ID: 1638534
[TBL] [Abstract][Full Text] [Related]
8. Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers.
Jego N; Thomas G; Hamelin R
Oncogene; 1993 Jan; 8(1):209-13. PubMed ID: 8380918
[TBL] [Abstract][Full Text] [Related]
9. Mutations in p53 as potential molecular markers for human breast cancer.
Runnebaum IB; Nagarajan M; Bowman M; Soto D; Sukumar S
Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10657-61. PubMed ID: 1961733
[TBL] [Abstract][Full Text] [Related]
10. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer.
Kohler MF; Marks JR; Wiseman RW; Jacobs IJ; Davidoff AM; Clarke-Pearson DL; Soper JT; Bast RC; Berchuck A
J Natl Cancer Inst; 1993 Sep; 85(18):1513-9. PubMed ID: 8360934
[TBL] [Abstract][Full Text] [Related]
11. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
12. A frequent deletion polymorphism on chromosome 22q13 identified by representational difference analysis of ovarian cancer.
Lin H; Pizer ES; Morin PJ
Genomics; 2000 Nov; 69(3):391-4. PubMed ID: 11056057
[TBL] [Abstract][Full Text] [Related]
13. Novel polymerase chain reaction approach for full-coding p53 mutation detection in microdissected archival tumors.
Thompson-Hehir J; Davies MP; Green JA; Halliwell N; Joyce KA; Salisbury J; Sibson DR; Vergote I; Walker C
Diagn Mol Pathol; 2000 Jun; 9(2):110-9. PubMed ID: 10850547
[TBL] [Abstract][Full Text] [Related]
14. High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic.
Vasickova P; Machackova E; Lukesova M; Damborsky J; Horky O; Pavlu H; Kuklova J; Kosinova V; Navratilova M; Foretova L
BMC Med Genet; 2007 Jun; 8():32. PubMed ID: 17561994
[TBL] [Abstract][Full Text] [Related]
15. p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines.
Skilling JS; Squatrito RC; Connor JP; Niemann T; Buller RE
Gynecol Oncol; 1996 Jan; 60(1):72-80. PubMed ID: 8557231
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms possibly affecting WT1 function in human ovarian tumors.
Viel A; Giannini F; Capozzi E; Canzonieri V; Scarabelli C; Gloghini A; Boiocchi M
Int J Cancer; 1994 May; 57(4):515-21. PubMed ID: 7910152
[TBL] [Abstract][Full Text] [Related]
17. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
Schultz DC; Vanderveer L; Buetow KH; Boente MP; Ozols RF; Hamilton TC; Godwin AK
Cancer Res; 1995 May; 55(10):2150-7. PubMed ID: 7743516
[TBL] [Abstract][Full Text] [Related]
18. p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases.
Yamada Y; Yoshida T; Hayashi K; Sekiya T; Yokota J; Hirohashi S; Nakatani K; Nakano H; Sugimura T; Terada M
Cancer Res; 1991 Nov; 51(21):5800-5. PubMed ID: 1933850
[TBL] [Abstract][Full Text] [Related]
19. p53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma.
McManus DT; Murphy M; Arthur K; Hamilton PW; Russell SE; Toner PG
J Pathol; 1996 Jun; 179(2):177-82. PubMed ID: 8758210
[TBL] [Abstract][Full Text] [Related]
20. p53 gene mutations and protein accumulation in human ovarian cancer.
Kupryjańczyk J; Thor AD; Beauchamp R; Merritt V; Edgerton SM; Bell DA; Yandell DW
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):4961-5. PubMed ID: 8506342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
